<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194037</url>
  </required_header>
  <id_info>
    <org_study_id>HL-143IFN-SC-US-001</org_study_id>
    <nct_id>NCT01194037</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C</brief_title>
  <official_title>A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of ascending
      doses of Hanferon™ in combination with ribavirin (RBV). The secondary objective of this study
      is to define the PK and PD of ascending doses of Hanferon™ in combination with RBV. The
      exploratory objective of this study is to make a preliminary assessment of Hanferon™ efficacy
      in combination with RBV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA level</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who reach RVR</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK &amp; PD</measure>
    <time_frame>Weeks 0 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <condition>Genotype 1</condition>
  <arm_group>
    <arm_group_label>Hanferon (low dose) sc weekly + RBV oral daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hanferon (high dose) sc weekly + RBV oral daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys 180 ug sc weekly + RBV oral daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant variant of interferon-alpha 2b</intervention_name>
    <description>SC, Weekly</description>
    <arm_group_label>Hanferon (low dose) sc weekly + RBV oral daily</arm_group_label>
    <arm_group_label>Hanferon (high dose) sc weekly + RBV oral daily</arm_group_label>
    <other_name>Hanferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>SC Weekly</description>
    <arm_group_label>Pegasys 180 ug sc weekly + RBV oral daily</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic hepatitis C genotype 1a or 1b

          -  Male or female aged 18 to 65 years, inclusive

          -  Compensated liver disease without evidence of cirrhosis

          -  No evidence of type 1 or 2 diabetes mellitus, lipodystrophy or polycystic ovary
             syndrome

          -  No history or presence of autoimmune or lymphoproliferative disease or
             hemoglobinopathies

          -  Stable medication doses for 1 month for the chronic disease if subjects have chronic
             diseases, including but not limited to hypertension and dyslipidemia

        Exclusion Criteria:

          -  History of previous treatment of hepatitis C

          -  Currently use medication for psychiatric illness including depression, suicidal
             ideation, and psychosis

          -  History or presence of chronic liver disease

          -  History of drug or alcohol abuse within the past year

          -  Evidence of active illicit drug use

          -  Clinically significant abnormal electrocardiogram (ECG) or rhythm strip

          -  Female subject who has a positive urine pregnancy test or who is lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Interferon</keyword>
  <keyword>Hanferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

